While there are targeted therapies for patients with HR+/HER2−, HR+/HER2+, HR−/HER2+ disease, triple-negative (TN) BC lacks HR and HER2, rendering ER and HER2 therapies ineffective [8]. The gene discussed is HR; the disease is breast cancer.